Sana Biotechnology Inc (SANA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $605.26M
Last updated: Nov 17, 2026 at 11:06 AM ET
Sana Biotechnology Inc (SANA) Financials: Revenue, Profit and Cash Flow
Sana Biotechnology reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$244.17M, operating cash flow was -$143.83M and free cash flow was -$144.77M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of $20.40M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $250.32M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.00K |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$1.00K |
| Research and development | $161.41M | $206.79M | $212.83M | $201.00M | $306.50M | $257.88M | $119.38M | $4.01M |
| Operating income | -$250.32M | -$272.72M | -$293.14M | -$272.56M | -$356.91M | -$286.15M | -$141.15M | -$8.22M |
| Net income | -$244.17M | -$266.76M | -$283.25M | -$269.48M | -$355.93M | -$285.31M | -$130.78M | -$13.25M |
| EBITDA | -$237.57M | -$261.73M | -$275.65M | -$257.61M | -$345.53M | -$280.13M | -$139.35M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $15.28M | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | -$3.05M | $0 | $0 | $0 | $7.64M | $0 | $0 | $0 | -$7.54M |
| Operating income | $18.51M | -$65.42M | -$48.61M | -$61.20M | -$43.52M | -$94.97M | -$50.63M | -$50.87M | -$61.76M | -$49.37M | -$110.72M | -$90.62M |
| Net income | $20.40M | -$63.63M | -$47.21M | -$58.83M | -$42.15M | -$93.80M | -$49.39M | -$49.07M | -$59.92M | -$50.29M | -$107.47M | -$88.12M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $40.20M by $31.67M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $416.89M | $501.02M | $565.30M | $822.72M | $1.13B | $730.30M | $415.19M | $34.33M |
| Current assets | $148.68M | $160.81M | $213.51M | $444.44M | $558.10M | $384.47M | $144.26M | $32.60M |
| Cash and equivalents | $71.87M | $127.57M | $133.52M | $176.76M | $253.03M | $124.81M | $80.03M | $30.63M |
| Total liabilities | $256.01M | $250.52M | $277.79M | $323.40M | $400.90M | $298.58M | $557.73M | $47.52M |
| Short-term debt | $40.20M | $0 | $0 | $55.34M | $51.38M | $3.71M | $1.34M | N/A |
| Shareholder equity | $160.88M | $250.50M | $287.51M | $499.31M | $728.50M | -$421.18M | -$142.54M | -$13.19M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $376.13M | $431.52M | $373.59M | $416.89M | $435.43M | $361.64M | $445.47M | $501.02M | $559.39M | $618.67M | $681.38M | $565.30M |
| Total liabilities | $195.76M | $276.95M | $254.35M | $256.01M | $240.12M | $239.09M | $236.39M | $250.52M | $266.91M | $279.02M | $306.24M | $277.79M |
| Cash and equivalents | $41.10M | $57.07M | $83.80M | $71.87M | $103.36M | $71.27M | $96.13M | $127.57M | $127.00M | $134.96M | $177.05M | $133.52M |
| Shareholder equity | $180.36M | $154.57M | $119.24M | $160.88M | $195.31M | $122.56M | $209.08M | $250.50M | $292.48M | $339.65M | $375.14M | $287.51M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$143.83M | -$223.15M | -$253.58M | -$290.05M | -$251.05M | -$137.98M | -$85.52M | -$13.49M |
| Capital expenditures | $938.00K | $33.43M | $20.03M | $20.88M | $29.86M | $23.87M | $26.12M | $460.00K |
| Free cash flow | -$144.77M | -$256.58M | -$273.61M | -$310.93M | -$280.92M | -$161.85M | -$111.64M | -$13.96M |
| Investing cash flow | -$40.24M | $17.45M | $172.01M | $210.56M | -$245.80M | -$252.56M | -$87.86M | -$780.00K |
| Financing cash flow | $128.73M | $199.75M | $31.65M | $4.91M | $631.75M | $435.69M | $223.74M | $45.72M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$38.75M | -$32.79M | -$37.38M | -$32.64M | -$29.43M | -$33.10M | -$48.66M | -$47.16M | -$51.82M | -$58.54M | -$65.63M | -$51.96M |
| Capital expenditures | $791.00K | $1.62M | $288.00K | $873.00K | $41.00K | $112.00K | $136.00K | $436.00K | $4.09M | $13.06M | $15.85M | $14.05M |
| Free cash flow | -$39.54M | -$34.41M | -$37.67M | -$33.51M | -$29.47M | -$33.21M | -$48.79M | -$47.60M | -$55.91M | -$71.60M | -$81.48M | -$66.00M |
Frequently Asked Questions About SANA
What is Sana Biotechnology's annual revenue?
Sana Biotechnology reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Sana Biotechnology profitable?
No. Sana Biotechnology reported net income of -$244.17M for the fiscal year ended Dec 31, 2025.
How much free cash flow does SANA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$143.83M minus capital expenditures of $938.00K produced free cash flow of -$144.77M.
How much debt does Sana Biotechnology have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $40.20M and cash and equivalents of $71.87M.
SANA pages: Overview, Earnings, Forecast, Financials, Competitors